Petco Health & Wellness Co., Inc. (WOOF)

NASDAQConsumer DiscretionarySpecialty RetailSnapshot 2026-10-23

$2.45-3.16%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Petco Health & Wellness Co., Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.9%

+10% or more+5%0%−5%−10% or less

0.26 → 0.25 EPS · FY ending Jan 31, 2028 · 5 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 5 to 5; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q3
Revenue	—	1.47B
EPS	—	0.043
EBITDA	$100M–$103Mnon-GAAP	—
Revenue growth	0.4%–1%	—
FY 2026 · Annual
Revenue	—	5.99B
EPS	—	0.256
Capital expenditure	About $140M	—
EBITDA	$415M–$430Mnon-GAAP	—
EBITDA (Adjusted EBITDA 2 outlook)	$6.8Mnon-GAAP	—
FY 2027 · Annual
Revenue	—	6.05B
EPS	—	0.253

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
EPS remains positive and improves	A supporting condition in Petco Health & Wellness Co., Inc.'s published investment case. The stated target is EPS >= $0.07 next quarter and >= $0.22 FY26.	Improving	EPS falls below $0.07 next quarter or below $0.22 for FY26	Diluted EPS: $0.13 per share FY2026-Q2; GAAP. Published target: EPS >= $0.07 next quarter and >= $0.22 FY26. Target period is not explicitly aligned with this observation. Source published Sep 4, 20260.13 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Aug 1, 2026 Source: company_financial_results. Reference: a9673519-ce4a-47d8-a372-469a4a77d2e8. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating income improves from $24.6 million	Management aims to improve operating income from $24.6 million in Q1 2026.	Broken	operating income falls below $24.6 million	Operating income: $47.812M FY2026-Q2; GAAP. Published target: >= $24.6 million per quarter. Target period is not explicitly aligned with this observation. Source published Sep 4, 202647,812,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Aug 1, 2026 Source: company_financial_results. Reference: a9673519-ce4a-47d8-a372-469a4a77d2e8. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Operating income rose from $43.0 million in Q2 2025 to $47.8 million in Q2 2026 (+11.1%) with margin expansion of 32 basis points to 3.2%. In Q1 2026, operating income increased 50.5% to $24.6 million from $16.4 million in Q1 2025. Management consistently reaffirmed profitability targets, indicating delivery on improving profitability. Delivery assessment Oct 24, 2026
Quarterly revenue stabilizes near $1.5 billion	Revenue growth is targeted to stabilize near $1.5 billion quarterly.	Intact	quarterly revenue falls below $1.49 billion	Revenue: $1.489B FY2026-Q2; GAAP. Published target: >= $1.49 billion per quarter. Target period is not explicitly aligned with this observation. Source published Sep 4, 20261,489,220,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Aug 1, 2026 Source: company_financial_results. Reference: a9673519-ce4a-47d8-a372-469a4a77d2e8. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-01-31 · fmp

FY2028 EPS$0.25

$0.25 → $0.25 · observed estimates

FY2028 revenue$6.05B

$6.07B → $6.05B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.25	$6,073,538,660	5 / 8
2026-07-25	$0.25	$6,073,538,660	5 / 8
2026-07-26	$0.25	$6,073,538,660	5 / 8
2026-07-27	$0.25	$6,073,538,660	5 / 8
2026-07-28	$0.25	$6,073,538,660	5 / 8
2026-07-29	$0.25	$6,073,538,660	5 / 8
2026-07-30	$0.25	$6,073,538,660	5 / 8
2026-07-31	$0.25	$6,073,538,660	5 / 8
2026-08-01	$0.25	$6,073,538,660	5 / 8
2026-08-02	$0.25	$6,073,538,660	5 / 8
2026-08-03	$0.25	$6,073,538,660	5 / 8
2026-08-04	$0.25	$6,073,538,660	5 / 8
2026-08-05	$0.25	$6,073,538,660	5 / 8
2026-08-06	$0.25	$6,073,538,660	5 / 8
2026-08-08	$0.25	$6,073,538,660	5 / 8
2026-08-09	$0.25	$6,073,538,660	5 / 8
2026-08-10	$0.25	$6,073,538,660	5 / 8
2026-08-12	$0.25	$6,073,538,660	5 / 8
2026-08-13	$0.28	$6,086,132,330	8 / 12
2026-08-14	$0.25	$6,073,538,660	5 / 8
2026-08-15	$0.25	$6,073,538,660	5 / 8
2026-08-16	$0.25	$6,073,538,660	5 / 8
2026-08-17	$0.25	$6,073,538,660	5 / 8
2026-08-18	$0.25	$6,073,538,660	5 / 8
2026-08-19	$0.25	$6,073,538,660	5 / 8
2026-08-20	$0.25	$6,074,038,660	5 / 8
2026-08-21	$0.25	$6,074,038,660	5 / 8
2026-08-22	$0.25	$6,074,038,660	5 / 8
2026-08-23	$0.25	$6,074,038,660	5 / 8
2026-08-24	$0.25	$6,074,038,660	5 / 8
2026-08-25	$0.25	$6,074,038,660	5 / 8
2026-08-26	$0.25	$6,074,038,660	5 / 8
2026-08-27	$0.25	$6,074,038,660	5 / 8
2026-08-28	$0.25	$6,074,038,660	5 / 8
2026-08-29	$0.25	$6,074,038,660	5 / 8
2026-08-30	$0.25	$6,074,038,660	5 / 8
2026-08-31	$0.25	$6,074,038,660	5 / 8
2026-09-01	$0.25	$6,074,038,660	5 / 8
2026-09-02	$0.25	$6,074,038,660	5 / 8
2026-09-03	$0.25	$6,057,826,879	5 / 8
2026-09-04	$0.26	$6,053,139,891	5 / 8
2026-09-05	$0.26	$6,053,139,891	5 / 8
2026-09-06	$0.26	$6,053,139,891	5 / 8
2026-09-07	$0.26	$6,053,139,891	5 / 8
2026-09-08	$0.26	$6,053,139,891	5 / 8
2026-09-09	$0.26	$6,053,139,891	5 / 8
2026-09-10	$0.26	$6,053,139,891	5 / 8
2026-09-11	$0.26	$6,053,139,891	5 / 8
2026-09-12	$0.26	$6,053,139,891	5 / 8
2026-09-13	$0.26	$6,053,139,891	5 / 8
2026-09-14	$0.26	$6,053,139,891	5 / 8
2026-09-15	$0.26	$6,053,139,891	5 / 8
2026-09-16	$0.26	$6,053,139,891	5 / 8
2026-09-17	$0.26	$6,053,139,891	5 / 8
2026-09-18	$0.26	$6,053,139,891	5 / 8
2026-09-19	$0.26	$6,053,139,891	5 / 8
2026-09-20	$0.26	$6,053,139,891	5 / 8
2026-09-21	$0.26	$6,053,139,891	5 / 8
2026-09-22	$0.26	$6,053,139,891	5 / 8
2026-09-23	$0.26	$6,053,139,891	5 / 8
2026-09-24	$0.26	$6,053,139,891	5 / 8
2026-09-25	$0.26	$6,053,139,891	5 / 8
2026-09-26	$0.26	$6,053,139,891	5 / 8
2026-09-27	$0.26	$6,053,139,891	5 / 8
2026-09-28	$0.26	$6,053,139,891	5 / 8
2026-09-29	$0.26	$6,053,138,829	5 / 8
2026-09-30	$0.26	$6,053,138,829	5 / 8
2026-10-01	$0.26	$6,053,138,831	5 / 8
2026-10-02	$0.26	$6,053,138,831	5 / 8
2026-10-03	$0.26	$6,053,138,831	5 / 8
2026-10-04	$0.26	$6,053,161,908	5 / 8
2026-10-05	$0.26	$6,053,161,908	5 / 8
2026-10-06	$0.26	$6,064,102,400	5 / 8
2026-10-07	$0.26	$6,064,102,400	5 / 8
2026-10-08	$0.25	$6,064,102,400	5 / 8
2026-10-09	$0.25	$6,064,102,400	5 / 7
2026-10-10	$0.25	$6,064,102,400	5 / 7
2026-10-11	$0.25	$6,064,102,400	5 / 7
2026-10-12	$0.25	$6,064,102,400	5 / 7
2026-10-13	$0.25	$6,064,102,400	5 / 7
2026-10-14	$0.25	$6,064,102,400	5 / 7
2026-10-15	$0.25	$6,064,102,400	5 / 7
2026-10-16	$0.25	$6,064,102,400	5 / 7
2026-10-17	$0.25	$6,064,102,400	5 / 7
2026-10-18	$0.25	$6,064,102,400	5 / 7
2026-10-19	$0.25	$6,064,102,400	5 / 7
2026-10-20	$0.25	$6,064,102,400	5 / 7
2026-10-21	$0.25	$6,064,102,400	5 / 7
2026-10-22	$0.25	$6,064,102,400	5 / 7
2026-10-23	$0.25	$6,064,102,400	5 / 7
2026-10-24	$0.25	$6,051,979,754	5 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	2	8	2
2026-06-01	2	8	2
2026-07-01	2	8	2
2026-08-01	2	8	2
2026-09-01	2	8	2
2026-10-01	2	8	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 8 Hold · 2 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

EPS remains positive and improvesDiluted EPS: $0.13 per share
Operating income improves from $24.6 millionPublished status: Broken
Quarterly revenue stabilizes near $1.5 billionRevenue: $1.489B

Next proof point

Nov 24, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.7%Typical daily move · historical

Downside history

-42.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Petco Health & Wellness Co., Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a turnaround-style business with a multi-year view that depends on turning modest sales growth into sustained profits. The thesis is currently intact, and recent momentum improved, though the company remains loss-making overall and risk is elevated.

What's priced into Petco Health & Wellness Co., Inc.

The valuation evidence is mixed: WOOF is described as cheap versus peers, while the model also shows a premium to peers and a negative expectations gap. The overall priced-in assessment is justified, with low fragility, but the evidence does not show that expectations are clearly undemanding.

What the fundamentals likely do

Near term, recent results show roughly flat sales with slight comparable-sales growth, alongside higher operating income and wider margins. Management has reaffirmed its profitability priorities, while a recent earnings beat and improving momentum support the thesis; CEO and CFO transitions add uncertainty, and capital spending discipline remains under watch.

What Petco Health & Wellness Co., Inc. hinges on

The multi-year thesis hinges on management sustaining sales growth and improving profitability despite leadership changes. Near term, a guidance cut would weaken confidence, while continued strength from large consumer-discretionary companies could support the sector backdrop; weaker results from those companies could remove that support.